Sarcopenic obesity and osteoporosis: Research progress and hot spots DOI Creative Commons

Shangheng Fan,

Yulan Cai,

Yunqin Wei

и другие.

Experimental Gerontology, Год журнала: 2024, Номер 195, С. 112544 - 112544

Опубликована: Авг. 22, 2024

Sarcopenic obesity (SO) and osteoporosis (OP) are associated with aging obesity. The pathogenesis of SO is complex, including glucolipid skeletal muscle metabolic disorders caused by inflammation, insulin resistance, other factors. Growing evidence links damage to bone loss. Muscle-lipid metabolism disrupt the balance between formation resorption, increasing risk OP. Conversely, bones also play a role in fat metabolism. In context obesity, comprehensive review focuses on effects mechanical stimulation, mesenchymal stem cells (MSCs), chronic myokines, adipokines musculoskeletal, at same time, impact osteokines muscle-lipid were analyzed. So far, exercise combined diet therapy most effective strategy for musculoskeletal mass. A holistic treatment diseases still preliminary exploration stage. Therefore, this article aims improve understanding -fat interactions OP, explores targets that can provide discusses current limitations challenges. We hope relevant ideas developing specific therapies improving disease prognosis future.

Язык: Английский

Sarcopenic obesity in older adults: a clinical overview DOI
Carla M. Prado, John A. Batsis, Lorenzo M. Donini

и другие.

Nature Reviews Endocrinology, Год журнала: 2024, Номер 20(5), С. 261 - 277

Опубликована: Фев. 6, 2024

Язык: Английский

Процитировано

61
Mitochondrial quality control in human health and disease DOI Creative Commons
Bohao Liu,

Chen-Zhen Xu,

Yi Liu

и другие.

Military Medical Research, Год журнала: 2024, Номер 11(1)

Опубликована: Май 29, 2024

Abstract Mitochondria, the most crucial energy-generating organelles in eukaryotic cells, play a pivotal role regulating energy metabolism. However, their significance extends beyond this, as they are also indispensable vital life processes such cell proliferation, differentiation, immune responses, and redox balance. In response to various physiological signals or external stimuli, sophisticated mitochondrial quality control (MQC) mechanism has evolved, encompassing key like biogenesis, dynamics, mitophagy, which have garnered increasing attention from researchers unveil specific molecular mechanisms. this review, we present comprehensive summary of primary mechanisms functions regulators involved major components MQC. Furthermore, critical regulated by MQC its diverse roles progression systemic diseases been described detail. We discuss agonists antagonists targeting MQC, aiming explore potential therapeutic research prospects enhancing stabilize function.

Язык: Английский

Процитировано

37
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies DOI Open Access
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek

и другие.

Pharmacological Reviews, Год журнала: 2024, Номер 76(3), С. 454 - 499

Опубликована: Янв. 30, 2024

Steatotic liver disease (SLD) displays a dynamic and complex phenotype. Consequently, the metabolic dysfunction-associated steatotic (MASLD)/metabolic steatohepatitis (MASH) therapeutic pipeline is expanding rapidly in multiple directions. In parallel, non-invasive tools for diagnosing monitoring responses to interventions are being studied, clinically feasible findings explored as primary outcomes interventional trials. The realization that distinct subgroups exist under umbrella of SLD should guide more precise personalized treatment recommendations facilitate advancements pharmacotherapeutics. This review summarizes recent updates pathophysiology-based nomenclature outlines both effective pharmacotherapeutics those MASLD/MASH, detailing their mode action current status phase 2 3 clinical Of extensive arsenal MASLD/MASH pipeline, several have been rejected, whereas other, mainly monotherapy options, shown only marginal benefits now tested part combination therapies, yet others still development monotherapies. Although successful drug candidate (or combinations) remains elusive, such approaches will ideally target MASH fibrosis while improving cardiometabolic risk factors. Due urgent need novel strategies potential availability safety tolerability data, repurposing existing approved drugs an appealing option. Finally, it essential highlight and, by extension, MASLD be recognized approached systemic affecting organs, with vigorous implementation interdisciplinary coordinated plans. Significance Statement SLD, including, among others, MASH, considered most prevalent chronic condition than one-fourth global population. aims provide information regarding pathophysiology, diagnosis, management line guidelines Collectively, hoped provided furthers understanding state direct implications stimulates additional research initiatives.

Язык: Английский

Процитировано

36
Sarcopenic Obesity and Cardiovascular Disease: An Overlooked but High-Risk Syndrome DOI Creative Commons
Saeid Mirzai, Salvatore Carbone, John A. Batsis

и другие.

Current Obesity Reports, Год журнала: 2024, Номер 13(3), С. 532 - 544

Опубликована: Май 16, 2024

Sarcopenic obesity (SO), defined as the coexistence of excess fat mass and reduced skeletal muscle strength, has emerged an important cardiovascular risk factor, particularly in older adults. This review summarizes recent findings on diagnosis, prevalence, health impacts, treatment SO.

Язык: Английский

Процитировано

19
Sarcopenia in MASLD—Eat to Beat Steatosis, Move to Prove Strength DOI Open Access
Dana Crișan, Lucreţia Avram,

Andreea Morariu-Barb

и другие.

Nutrients, Год журнала: 2025, Номер 17(1), С. 178 - 178

Опубликована: Янв. 2, 2025

The connections between sarcopenia and various chronic conditions, including type 2 diabetes (T2DM), metabolic syndrome (MetS), liver disease have been highlighted recently. There is also a high occurrence of in dysfunction-associated steatotic (MASLD) patients, who are often disregarded. Both experimental clinical findings suggest complex, bidirectional relationship MASLD sarcopenia. While vitamin D, testosterone, specific drug therapies show promise mitigating sarcopenia, consensus on effective treatments lacking. Recent focus lifestyle interventions emphasizes dietary therapy exercise for sarcopenic obesity MASLD. Challenges arise as weight loss, primary treatment, may lead to muscle mass reduction. therapeutic approach morbidly obese patients includes bariatric surgery (BS). BS induces loss stabilizes imbalances, but its impact nuanced, underscoring the need further research. Our aim provide comprehensive review interplay offer insight into most recent challenges discoveries, overlooked or unrecognized poses significant managing these patients.

Язык: Английский

Процитировано

2
Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease DOI
Stergios A. Pοlyzos, Ilias D. Vachliotis, Christos S. Mantzoros

и другие.

Metabolism, Год журнала: 2023, Номер 147, С. 155676 - 155676

Опубликована: Авг. 4, 2023

Язык: Английский

Процитировано

40
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis DOI
Paschalis Karakasis, Dimitrios Patoulias,

Nikolaos Fragakis

и другие.

Metabolism, Год журнала: 2024, Номер unknown, С. 156113 - 156113

Опубликована: Дек. 1, 2024

Язык: Английский

Процитировано

12
Nutritional and functional outcomes in trials of nutrient‐stimulated hormone‐based therapy—A systematic mapping review DOI Creative Commons
Sébastien Czernichow, Nathalie Rassy, Claire Carette

и другие.

Obesity Reviews, Год журнала: 2025, Номер unknown

Опубликована: Янв. 27, 2025

Summary Introduction Currently, trials are investigating the efficacy of nutrient‐stimulated hormone‐based therapies (NuSHs) in promoting weight loss people living with overweight and obesity. However, extent to which nutritional functional outcomes evaluated remains uncertain. Thus, we conducted a systematic mapping assess presence randomized controlled (RCTs) NuSHs. Methods We search on Cochrane Central Register Controlled Trials (CENTRAL), includes ClinicalTrials.gov International Clinical Registry Platform for interventional NuSHs registered from inception December 31, 2023. excluded non‐ quasi‐randomized trials, phase I that did not include body as primary or secondary outcome, an intervention duration less than 6 months, specify mass index threshold their eligibility criteria. Outcomes included: dietary intake, eating behavior, composition, physical performance, muscle strength, bone health, levels vitamins, trace elements, albumin, prealbumin, hemoglobin. Results The identified 2284 417 were included analysis. proportion RCTs assessment other increased over time. Approximately, 20.4% reported measurements 17.3% albumin/prealbumin/hemoglobin, 17% intake behavior. Evaluations vitamins/trace elements 5% total each. Conclusion present review has shown sparse reporting evaluating impact

Язык: Английский

Процитировано

1
Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management DOI Creative Commons
Thomas M. Barber, Stefan Kabisch, A. Pfeiffer

и другие.

Metabolites, Год журнала: 2025, Номер 15(2), С. 85 - 85

Опубликована: Фев. 1, 2025

The ‘Body Mass Index’ (BMI) is an anachronistic and outdated ratio that used as internationally accepted diagnostic criterion for obesity, to prioritise, stratify, outcome-assess its management options. On individual level, the BMI has potential mislead, including inaccuracies in cardiovascular risk assessment. Furthermore, places excessive emphasis on a reduction overall body weight (rather than optimised composition) contributes towards misunderstanding of quiddity obesity dispassionate societal perspective response global problem. objective this review provide overview transitions away from novel vista: viewing skeletal muscle (SM). We resurrect SM tissue hidden plain sight key role plays influencing metabolic health efficiency. discuss complex interlinks between adipose (AT) through myokines adipokines, argue rather two separate tissues, AT should be considered single entity: ‘Adipo–Muscle Axis’. vicious circle sarcopenic which aging- obesity-related decline mass worsened status insulin resistance, turn further compounds function. approaches can mitigate against context negative energy balance, optimisation dietary protein intake resistance physical exercises, molecules development target SM, will play important future obesity. Finally, we Adipo–Muscle Ratio (AMR) would more clinically meaningful descriptor definition help shift our focus regarding effective merely inducing loss optimising AMR with proper attention maintenance augmentation

Язык: Английский

Процитировано

1
BMI Association With Treatment Outcomes in Head and Neck Cancer Patients Receiving Immunotherapy: A Comprehensive Review and Meta‐Analysis DOI Creative Commons
Sakditad Saowapa, Natchaya Polpichai,

Pharit Siladech

и другие.

Cancer Reports, Год журнала: 2025, Номер 8(2)

Опубликована: Фев. 1, 2025

ABSTRACT Background In recent years, immunotherapy using immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced malignancies. As such, numerous ICIs are establishing themselves as prospective therapy alternatives for individuals with head and neck cancer (HNC). Evidence suggests a potential correlation between body mass index (BMI) efficacy in patients. However, this association HNC patients subjected to is still unclear. Aims To investigate effect BMI on survival outcomes treated immunotherapy. Methods PubMed, Web Science, Google Scholar databases were searched extensively records published until January 2024. Full‐text articles aligned research objective included, while English, case reports, reviews, editorials, studies reporting combined other therapies excluded. The data required review analysis was abstracted Excel files by two independent reviewers. Additionally, synthesis carried out Review Manager program, evaluation methodological quality done Newcastle Ottawa scale. statistical analyses stratified according values, which categorized follows: Obese (BMI ≥ 27.5), non‐obese < overweight (BMI: 23.5–27.5), underweight 18.5), normal 18.5–23.5), low 20), high 20). Results Only six reviewed analyzed. A subgroup from these showed that obese had significantly better overall (OS) rates than (HR: 0.51; 95% CI: 0.29–0.93; p = 0.03). progression‐free (PFS) statistically similar 0.72; 0.39–1.33; 0.30). addition, when either or high, no significant difference observed OS PFS 0.99; 0.59–1.66; 0.97 HR: 0.93; 0.61–1.41; 0.42, respectively). Similarly, have 0.53; 0.15–1.92; 0.33 0.55; 0.20–1.52; 0.25, contrast, demonstrated poor 2.56; 1.29–5.12; 0.008 2.76; 1.17–6.52; 0.02, Discussion Conclusion tend improved patients, worse clinical prognoses those above BMI.

Язык: Английский

Процитировано

1